New Phase 3 Trial Explores Shorter Treatment Path for Drug-Resistant Tuberculosis

A new Phase 3 clinical trial has begun enrolling participants to evaluate treatment regimens containing quabodepistat, an investigational compound being studied for its potential to help combat drug-resistant tuberculosis (TB). This randomized, multicenter study represents an important step forward in the ongoing effort to find faster and more effective treatments for one of the world’s most persistent infectious diseases.

The trial is structured around two patient cohorts based on whether their TB strain is susceptible or resistant to fluoroquinolone antibiotics. In the fluoroquinolone-susceptible group, researchers will compare a shortened four-month experimental regimen combining bedaquiline, pretomanid, quabodepistat, and moxifloxacin against the current six-month standard-of-care combination. If successful, this could mean patients spend two fewer months undergoing treatment, a meaningful improvement for quality of life and treatment adherence.

For participants with fluoroquinolone-resistant TB, a six-month quabodepistat-based regimen will be compared to existing therapy. Including this harder-to-treat population is especially valuable, as drug-resistant TB strains have historically posed some of the greatest challenges in infectious disease treatment, often requiring longer and more complex drug combinations.

With approximately 532 participants planned across both cohorts, the study is designed with rigorous safeguards, including a blinded Endpoint Adjudication Committee that will independently confirm treatment outcomes. This level of scientific oversight reflects a strong commitment to generating reliable, trustworthy data that could eventually inform updated treatment guidelines for drug-resistant pulmonary TB worldwide.

Shortening TB treatment duration while maintaining or improving efficacy has long been a goal for researchers and public health officials, as longer treatment courses can strain healthcare systems and make it harder for patients to complete their full regimen. Trials like this one offer hope that new drug combinations may soon make treatment more manageable for patients facing this serious disease.

This article is for informational purposes only and is not intended as medical advice.

Curated by True North Labs. More at truenorthlabs.co. Informational only – not medical advice.

Source: Clinical Trial: A Study of Quabodepistat-containing Regimens for the Treatment of Drug-resistant Pulmonary Tuberculosis